Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL874265 | 0.95 | TRPV1 (0.65) | L3MBTL1HPGDMCL1GAATRPV1 | |
| SCHEMBL2265490 | 0.90 | MCL1 (0.70) | L3MBTL1HPGDMCL1GAANPC1 | |
| SCHEMBL6214475 | 0.82 | KMT2A (0.55) | L3MBTL1HPGDGAANPC1RAB9A | |
| SCHEMBL654148 | 0.80 | MCL1 (1.00) | L3MBTL1HPGDMCL1GAARAB9A | |
| SCHEMBL13209218 | 0.80 | GAA (1.00) | L3MBTL1HPGDGAATRPV1NPC1 | |
| SCHEMBL11976711 | 0.80 | L3MBTL1 (0.77) | L3MBTL1HPGDGAATRPV1NPC1 | |
| SCHEMBL7201053 | 0.80 | L3MBTL1 (0.89) | L3MBTL1HPGDGAATRPV1NPC1 | |
| SCHEMBL17529336 | 0.78 | TRPV1 (0.56) | MCL1TRPV1NPC1RAB9AEPHX2 | |
| SCHEMBL12500390 | 0.78 | HPGD (0.64) | L3MBTL1HPGDGAATRPV1RAB9A | |
| SCHEMBL7598872 | 0.78 | L3MBTL1 (0.74) | L3MBTL1HPGDGAATRPV1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110862335-B | Preparation method of VEGFR2 selective inhibitor SU1498 | 安莱博医药(苏州)有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-110862335-A | Preparation method of VEGFR2 selective inhibitor SU1498 | 安莱博医药(苏州)有限公司 | 2020-03-06 | — | — | CN | disclosed |
| EP-1465869-B1 | MODULATORS OF LXR | EXELIXIS PATENT CO LLC (US) | 2013-05-15 | — | — | EP | disclosed |
| US-7998986-B2 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998986-B2 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7598419-B2 | Compounds for modulating cell proliferation | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2009-10-06 | — | — | US | disclosed |
| US-7598419-B2 | Compounds for modulating cell proliferation | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2009-10-06 | — | — | US | disclosed |
| US-7598419-B2 | Compounds for modulating cell proliferation | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2009-10-06 | — | — | US | disclosed |
| US-20070243612-A1 | Novel Compounds for Modulating Cell Proliferation | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2007-10-18 | — | — | US | disclosed |
| US-20070243612-A1 | Novel Compounds for Modulating Cell Proliferation | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2007-10-18 | — | — | US | disclosed |
| US-5789427-A | ANTITUMOR, ANTICANCER AGENTS | SUGEN, INC. (US) | 1998-08-04 | — | — | US | disclosed |
| US-5773476-A | KINASE INHIBITORS | SUGEN, INC. (IL) | 1998-06-30 | — | — | US | disclosed |
| US-5763441-A | ADMINISTERING TO THE PATIENT SUFFERING FROM DIABETES, GLIOMA, HEMANGIOMA, KAPOSI'S SARCOMA, OVARIAN/BREAST/PANCREATIC/COLON AND PROSTATE CANCER A BENZO(G)QUINOXALINE COMPOUNDS | SUGEN, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| US-5712395-A | BENZO(G)QUINOXALINE | YISSUM RESEARCH DEVELOPMENT CORP. (IL) | 1998-01-27 | — | — | US | disclosed |
| US-5700822-A | ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF ISOXAZOLE AMIDE DERIVATIOVE AND CYANO, HYDROXY, AROMATIC AMIDE DERIVATIVE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-12-23 | — | — | US | disclosed |
| EP-0804191-A1 | TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS CANCERS USING INHIBITORS OF PLATELET DERIVED GROWTH RECEPTOR | Sugen, Inc. (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0748219-A1 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | Sugen, Inc. (US) | 1996-12-18 | — | — | EP | disclosed |
| WO-1995024190-A2 | RECEPTOR TYROSINE KINASE INHIBITORS FOR INHIBITING CELL PROLIFERATIVE DISORDERS AND COMPOSITIONS THEREOF | SUGEN, INC. (US) | 1995-09-14 | — | — | WO | disclosed |
| WO-1995021613-A1 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | SUGEN, INC. (US) | 1995-08-17 | — | — | WO | disclosed |
| WO-1995019169-A2 | TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS CANCER USING INHIBITORS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR | SUGEN, INC. (US) | 1995-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070243612-A1 | Novel Compounds for Modulating Cell Proliferation | MKI67, CCNA1, PCNA | L3MBTL1 1852/4885HPGD 721/4885MCL1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.